Impaired Kidney Function and Atrial Fibrillation in Elderly Subjects

Journal of Cardiac Failure

Volumn 16, Issue 1, 2010, Pages 55-60

  Deo, Rajat ^a   Katz, Ronit ^b   Kestenbaum, Bryan ^c   Fried, Linda ^d   Sarnak, Mark J ^e   Psaty, Bruce M ^c   Siscovick, David S ^c   Shlipak, Michael G ^f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

arrhythmias; cystatin C; elderly; epidemiology; Kidney function

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGED; AMBULATORY CARE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; AGE; ATRIAL FIBRILLATION; COHORT ANALYSIS; COMPLICATION; CROSS-SECTIONAL STUDY; KIDNEY DISEASES; KIDNEY FUNCTION TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE;

EID: 72749102706     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2009.07.002     Document Type: Article

References (37)

1. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285 (2001) 2370-2375
2. Coresh J., Astor B., and Sarnak M.J. Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 13 (2004) 73-81
3. Weiner D.E., Tighiouart H., Amin M.G., Stark P.C., MacLeod B., Griffith J.L., et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 15 (2004) 1307-1315
4. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
5. Shlipak M.G., Katz R., Fried L.F., Jenny N.S., Stehman-Breen C.O., Newman A.B., et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol 45 (2005) 268-271
6. Shlipak M.G., Sarnak M.J., Katz R., Fried L.F., Seliger S.L., Newman A.B., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352 (2005) 2049-2060
7. Schrier R.W. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med 113 (1990) 155-159
8. Zucker I.H., Gorman A.J., Cornish K.G., and Lang M. Imparied atrial receptor modulation or renal nerve activity in dogs with chronic volume overload. Cardiovasc Res 19 (1985) 411-418
9. Madrid A.H., Bueno M.G., Rebollo J.M., Marin I., Pena G., Bernal E., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106 (2002) 331-336
10. Pedersen O.D., Bagger H., Kober L., and Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100 (1999) 376-380
11. Van Den Berg M.P., Crijns H.J., Van Veldhuisen D.J., Griep N., De Kam P.J., and Lie K.I. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail 1 (1995) 355-363
12. Vermes E., Tardif J.C., Bourassa M.G., Racine N., Levesque S., White M., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107 (2003) 2926-2931
13. Wachtell K., Lehto M., Gerdts E., Olsen M.H., Hornestam B., Dahlof B., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45 (2005) 712-719
14. Ueng K.C., Tsai T.P., Yu W.C., Tsai C.F., Lin M.C., Chan K.C., et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 24 (2003) 2090-2098
15. Nakashima H., Kumagai K., Urata H., Gondo N., Ideishi M., and Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 101 (2000) 2612-2617
16. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89 (2002) 3A-9A
17. Rocha R., and Stier Jr. C.T. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 12 (2001) 308-314
18. Weber K.T., and Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83 (1991) 1849-1865
19. Delcayre C., Silvestre J.S., Garnier A., Oubenaissa A., Cailmail S., Tatara E., et al. Cardiac aldosterone production and ventricular remodeling. Kidney Int 57 (2000) 1346-1351
20. Novo S., Adamo L., Giamporcaro A., Forte G., Longo B., Gallo V.B., et al. Changes of angiotensin converting enzyme (ACE) levels during activation of the renin-angiotensin-aldosterone system (RAAs). Agents Actions Suppl 22 (1987) 339-347
21. Remuzzi G., Perico N., Macia M., and Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 99 (2005) S57-S65
22. Boldt A., Scholl A., Garbade J., Resetar M.E., Mohr F.W., Gummert J.F., et al. ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol 10 (2006) 261-267
23. Fried L.P., Borhani N.O., Enright P., Furberg C.D., Gardin J.M., Kronmal R.A., et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1 (1991) 263-276
24. Cushman M., Cornell E.S., Howard P.R., Bovill E.G., and Tracy R.P. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 41 (1995) 264-270
25. Furberg C.D., Psaty B.M., Manolio T.A., Gardin J.M., Smith V.E., and Rautaharju P.M. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 74 (1994) 236-241
26. Rautaharju P.M., MacInnis P.J., Warren J.W., Wolf H.K., Rykers P.M., and Calhoun H.P. Methodology of ECG interpretation in the Dalhousie program; NOVACODE ECG classification procedures for clinical trials and population health surveys. Methods Inf Med 29 (1990) 362-374
27. Psaty B.M., Manolio T.A., Kuller L.H., Kronmal R.A., Cushman M., Fried L.P., et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 96 (1997) 2455-2461
28. Erlandsen E.J., Randers E., and Kristensen J.H. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest 59 (1999) 1-8
29. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
30. Shlipak M.G., Fried L.F., Cushman M., Manolio T.A., Peterson D., Stehman-Breen C., et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293 (2005) 1737-1745
31. Levey A.S., Coresh J., Balk E., Kausz A.T., Levin A., Steffes M.W., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
32. Aviles R.J., Martin D.O., Apperson-Hansen C., Houghtaling P.L., Rautaharju P., Kronmal R.A., et al. Inflammation as a risk factor for atrial fibrillation. Circulation 108 (2003) 3006-3010
33. Shi Y., Li D., Tardif J.C., and Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 54 (2002) 456-461
34. Ravelli F., and Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 96 (1997) 1686-1695
35. Wijffels M.C., Kirchhof C.J., Dorland R., and Allessie M.A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92 (1995) 1954-1968
36. Shi Y., Ducharme A., Li D., Gaspo R., Nattel S., and Tardif J.C. Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res 52 (2001) 217-225
37. Knight E.L., Verhave J.C., Spiegelman D., Hillege H.L., de Zeeuw D., Curhan G.C., et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65 (2004) 1416-1421